Emergent BioSolutions Files 8-K on Agreements and Obligations
Ticker: EBS · Form: 8-K · Filed: Sep 3, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Sep 3, 2024 |
| Risk Level | medium |
| Pages | 8 |
| Reading Time | 9 min |
| Key Dollar Amounts | $0.001, $250 m, $25,000,000, M, $75.0 million, $10,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
Emergent BioSolutions filed an 8-K detailing new deals, debt, and stock sales.
AI Summary
Emergent BioSolutions Inc. filed an 8-K on August 30, 2024, reporting the entry into and termination of material definitive agreements. The company also disclosed the creation of direct financial obligations and unregistered sales of equity securities. Additionally, the filing included Regulation FD disclosures and other events, along with financial statements and exhibits.
Why It Matters
This filing indicates significant corporate actions, including potential new financial commitments and equity transactions, which could impact the company's financial structure and shareholder value.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- August 30, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 300 Professional Drive, Gaithersburg, Maryland 20879 (address) — Business and Mail Address
FAQ
What specific material definitive agreements were entered into and terminated by Emergent BioSolutions?
The filing indicates the entry into and termination of material definitive agreements, but the specific details of these agreements are not provided in the summary information.
What are the details of the direct financial obligations created by Emergent BioSolutions?
The 8-K reports the creation of a direct financial obligation, but the specific nature and amount of this obligation are not detailed in the provided text.
What unregistered sales of equity securities are disclosed in this filing?
The filing mentions unregistered sales of equity securities, but the specifics regarding the type, amount, and terms of these sales are not included in the summary.
What is the nature of the Regulation FD Disclosure mentioned in the filing?
The filing indicates a Regulation FD Disclosure, but the content of this disclosure is not specified in the provided information.
What 'Other Events' are reported by Emergent BioSolutions in this 8-K filing?
The filing lists 'Other Events' as a category, but the specific events are not detailed in the provided summary text.
Filing Stats: 2,335 words · 9 min read · ~8 pages · Grade level 11.4 · Accepted 2024-09-03 07:47:30
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share EBS New York St
- $250 m — es for a term loan (the "Term Loan") of $250 million, which was drawn in full on the d
- $25,000,000, M — 2028 (the "Notes") outstanding exceeds $25,000,000, May 15, 2028, which is three months prior
- $75.0 million — (b) a minimum liquidity requirement of $75.0 million commencing on September 30, 2024 and te
- $10,000,000 — red unless the net cash proceeds exceed $10,000,000 in the aggregate per fiscal year or $5,
- $5,000,000 — 000 in the aggregate per fiscal year or $5,000,000 on a per-transaction basis) and (2) ins
- $10 million — Common Stock with an aggregate value of $10 million (the "Shares"), at a price per share eq
Filing Documents
- d873622d8k.htm (8-K) — 44KB
- d873622dex42.htm (EX-4.2) — 26KB
- d873622dex101.htm (EX-10.1) — 794KB
- d873622dex102.htm (EX-10.2) — 342KB
- d873622dex103.htm (EX-10.3) — 50KB
- d873622dex991.htm (EX-99.1) — 12KB
- 0001193125-24-211548.txt ( ) — 1674KB
- ebs-20240830.xsd (EX-101.SCH) — 3KB
- ebs-20240830_lab.xml (EX-101.LAB) — 17KB
- ebs-20240830_pre.xml (EX-101.PRE) — 11KB
- d873622d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 4.1 Form of Warrant (included in Exhibit 10.2). 4.2 First Supplemental Indenture, dated as of August 30, 2024, by and among Emergent BioSolutions Inc., the subsidiary guarantors party thereto and U.S. Bank Trust Company, National Association, as trustee. 10.1 Credit Agreement, dated as of August 30, 2024, by and among Emergent BioSolutions Inc., the lenders from time to time party thereto and OHA Agency LLC, as administrative agent. 10.2 Warrant Agreement between Emergent BioSolutions Inc. and Broadridge Corporate Issuer Solutions LLC, as Warrant Agent, dated August 30, 2024. 10.3 Form of Subscription Agreement, dated August 30, 2024, between Emergent BioSolutions Inc. and the Subscribing Entities. 99.1 Press release issued by Emergent BioSolutions Inc. on September 3, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). Certain confidential portions of this exhibit were omitted by means of marking such portions with asterisks because the identified information is (i) not material and (ii) the type of information that the registrant treats as private or confidential.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: September 3, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer